Previous 10 | Next 10 |
2023-12-05 17:53:48 ET More on PTC Therapeutics PTC Therapeutics, Inc. (PTCT) Q3 2023 Earnings Call Transcript PTC Therapeutics stock slides after Citi downgrades to Sell PTC Therapeutics GAAP EPS of -$1.76 misses by $0.70, revenue of $196.6M misses by $15.07M ...
PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities PR Newswire SOUTH PLAINFIELD, N.J. , Dec. 5, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities ...
2023-10-29 06:11:08 ET PTC Therapeutics, Inc. (PTCT) Q3 2023 Earnings Conference Call February 08, 2023, 9:00 AM ET Company Participants Jane Hanlon - Associate Director, Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Off...
2023-10-27 09:20:56 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Align Technology (NASDAQ: ALGN ) stock is on the move Friday after the Invisalign maker announced a $250 million share repurchase program . Align Technology notes that this ...
2023-10-27 09:08:01 ET PTC Therapeutics ( NASDAQ: PTCT ) plunged ~22% premarket on Friday after the Citi downgraded recommendation on its stock to Sell/High Risk. SA Quant system rates the stock as Hold The downgrade follows the company's third quarter earnings a...
2023-10-26 18:02:05 ET Gainers: CVRx ( VRX ) +29% . Eargo ( EAR ) +28% . DexCom ( DXCM ) +15% . Masimo Corporation ( MASI ) +13% . Groupon ( GRPN ) +9% . Losers: Enphase Energy ( ENPH ) -17% . PTC Therapeutics...
2023-10-26 16:28:40 ET More on PTC Therapeutics PTC Therapeutics: Struggling Still But Potential Remains PTC Therapeutics, Inc. (PTCT) Q2 2023 Earnings Call Transcript PTC Therapeutics Q3 2023 Earnings Preview Royalty Pharma to buy up to $1.5B of PTC Therapeu...
PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results PR Newswire – Third quarter 2023 total revenues of $197 million and remain on target for 2023 revenue guidance – – PTC strengthened its financial position fo...
PTC Therapeutics Inc. (PTCT) is expected to report $-0.85 for Q3 2023
2023-10-19 19:02:30 ET A new royalty deal was the fuel that powered biotech PTC Therapeutics (NASDAQ: PTCT) stock to a 15% gain on Thursday. That arrangement, which covers PTC's spinal muscular atrophy (SMA) treatment Evrysdi, features a hefty upfront payment that could also bring i...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....
CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review PR Newswire - PTC to submit a request for re-examination - WARREN, N.J. , June 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announce...
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients PR Newswire - FDA lifts PTC518 partial clinical hold based on PIVOT-HD data - - Conference call and webcast to be held ...